208 related articles for article (PubMed ID: 18220516)
21. Isoform-specific effect of apolipoprotein E on cell survival and beta-amyloid-induced toxicity in rat hippocampal pyramidal neuronal cultures.
Jordán J; Galindo MF; Miller RJ; Reardon CA; Getz GS; LaDu MJ
J Neurosci; 1998 Jan; 18(1):195-204. PubMed ID: 9412500
[TBL] [Abstract][Full Text] [Related]
22. Amyloid clearance defect in ApoE4 astrocytes is reversed by epigenetic correction of endosomal pH.
Prasad H; Rao R
Proc Natl Acad Sci U S A; 2018 Jul; 115(28):E6640-E6649. PubMed ID: 29946028
[TBL] [Abstract][Full Text] [Related]
23. Gene-environment interaction between lead and Apolipoprotein E4 causes cognitive behavior deficits in mice.
Engstrom AK; Snyder JM; Maeda N; Xia Z
Mol Neurodegener; 2017 Feb; 12(1):14. PubMed ID: 28173832
[TBL] [Abstract][Full Text] [Related]
24. Apolipoprotein E4 decreases whereas apolipoprotein E3 increases the level of secreted amyloid precursor protein after closed head injury.
Ezra Y; Oron L; Moskovich L; Roses AD; Beni SM; Shohami E; Michaelson DM
Neuroscience; 2003; 121(2):315-25. PubMed ID: 14521991
[TBL] [Abstract][Full Text] [Related]
25. Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and Aβ metabolism in apoE4-targeted replacement mice.
Hu J; Liu CC; Chen XF; Zhang YW; Xu H; Bu G
Mol Neurodegener; 2015 Mar; 10():6. PubMed ID: 25871773
[TBL] [Abstract][Full Text] [Related]
26. Middle-aged human apoE4 targeted-replacement mice show retention deficits on a wide range of spatial memory tasks.
Bour A; Grootendorst J; Vogel E; Kelche C; Dodart JC; Bales K; Moreau PH; Sullivan PM; Mathis C
Behav Brain Res; 2008 Nov; 193(2):174-82. PubMed ID: 18572260
[TBL] [Abstract][Full Text] [Related]
27. The pathological cross talk between apolipoprotein E and amyloid-beta peptide in Alzheimer's disease: emerging gene-based therapeutic approaches.
Iurescia S; Fioretti D; Mangialasche F; Rinaldi M
J Alzheimers Dis; 2010; 21(1):35-48. PubMed ID: 20182014
[TBL] [Abstract][Full Text] [Related]
28. Transcriptional Effects of ApoE4: Relevance to Alzheimer's Disease.
Theendakara V; Peters-Libeu CA; Bredesen DE; Rao RV
Mol Neurobiol; 2018 Jun; 55(6):5243-5254. PubMed ID: 28879423
[TBL] [Abstract][Full Text] [Related]
29. Characterization of the binding of amyloid-beta peptide to cell culture-derived native apolipoprotein E2, E3, and E4 isoforms and to isoforms from human plasma.
Yang DS; Smith JD; Zhou Z; Gandy SE; Martins RN
J Neurochem; 1997 Feb; 68(2):721-5. PubMed ID: 9003062
[TBL] [Abstract][Full Text] [Related]
30. APOE epsilon 3/ epsilon 4 heterozygotes have an elevated proportion of apolipoprotein E4 in cerebrospinal fluid relative to plasma, independent of Alzheimer's disease diagnosis.
Fukumoto H; Ingelsson M; Gårevik N; Wahlund LO; Nukina N; Yaguchi Y; Shibata M; Hyman BT; Rebeck GW; Irizarry MC
Exp Neurol; 2003 Sep; 183(1):249-53. PubMed ID: 12957508
[TBL] [Abstract][Full Text] [Related]
31. Human ApoE Isoforms Differentially Modulate Glucose and Amyloid Metabolic Pathways in Female Brain: Evidence of the Mechanism of Neuroprotection by ApoE2 and Implications for Alzheimer's Disease Prevention and Early Intervention.
Keeney JT; Ibrahimi S; Zhao L
J Alzheimers Dis; 2015; 48(2):411-24. PubMed ID: 26402005
[TBL] [Abstract][Full Text] [Related]
32. Neuronal Apolipoprotein E4 Expression Results in Proteome-Wide Alterations and Compromises Bioenergetic Capacity by Disrupting Mitochondrial Function.
Orr AL; Kim C; Jimenez-Morales D; Newton BW; Johnson JR; Krogan NJ; Swaney DL; Mahley RW
J Alzheimers Dis; 2019; 68(3):991-1011. PubMed ID: 30883359
[TBL] [Abstract][Full Text] [Related]
33. APOE and the regulation of microglial nitric oxide production: a link between genetic risk and oxidative stress.
Colton CA; Brown CM; Cook D; Needham LK; Xu Q; Czapiga M; Saunders AM; Schmechel DE; Rasheed K; Vitek MP
Neurobiol Aging; 2002; 23(5):777-85. PubMed ID: 12392781
[TBL] [Abstract][Full Text] [Related]
34. Neuroimaging biomarkers for Alzheimer's disease in asymptomatic APOE4 carriers.
Chételat G; Fouquet M
Rev Neurol (Paris); 2013 Oct; 169(10):729-36. PubMed ID: 24016463
[TBL] [Abstract][Full Text] [Related]
35. Structural differences between apoE3 and apoE4 may be useful in developing therapeutic agents for Alzheimer's disease.
Frieden C; Garai K
Proc Natl Acad Sci U S A; 2012 Jun; 109(23):8913-8. PubMed ID: 22615372
[TBL] [Abstract][Full Text] [Related]
36. Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer's disease.
Najm R; Jones EA; Huang Y
Mol Neurodegener; 2019 Jun; 14(1):24. PubMed ID: 31186040
[TBL] [Abstract][Full Text] [Related]
37.
Montagne A; Nikolakopoulou AM; Huuskonen MT; Sagare AP; Lawson EJ; Lazic D; Rege SV; Grond A; Zuniga E; Barnes SR; Prince J; Sagare M; Hsu CJ; LaDu MJ; Jacobs RE; Zlokovic BV
Nat Aging; 2021 Jun; 1(6):506-520. PubMed ID: 35291561
[TBL] [Abstract][Full Text] [Related]
38. Apolipoprotein E4 as a target for developing new therapeutics for Alzheimer's disease.
Refolo LM; Fillit HM
J Mol Neurosci; 2004; 23(3):151-5. PubMed ID: 15181243
[TBL] [Abstract][Full Text] [Related]
39. Clusterin accumulates in synapses in Alzheimer's disease and is increased in apolipoprotein E4 carriers.
Jackson RJ; Rose J; Tulloch J; Henstridge C; Smith C; Spires-Jones TL
Brain Commun; 2019; 1(1):fcz003. PubMed ID: 31853523
[TBL] [Abstract][Full Text] [Related]
40. The Interplay Between Apolipoprotein E4 and the Autophagic-Endocytic-Lysosomal Axis.
Schmukler E; Michaelson DM; Pinkas-Kramarski R
Mol Neurobiol; 2018 Aug; 55(8):6863-6880. PubMed ID: 29353455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
